Insititute for Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Department of Gastroenterology, Hepatology and Transplant Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Front Cell Infect Microbiol. 2022 Feb 2;12:804011. doi: 10.3389/fcimb.2022.804011. eCollection 2022.
Hepatitis B virus (HBV) infection causes acute and chronic liver diseases, including severe hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC). Interferon alpha 2a (IFNα-2a) is commonly used for treating chronic HBV infection. However, its efficacy remains relatively low. Yet, the immunological and molecular mechanisms for successful IFNα-2a treatment remain elusive. One issue is whether the application of increasing IFNα doses may modulate cellular processes and HBV replication in hepatic cells. In the present study, we focused on the interaction of IFNα signaling with other cellular signaling pathways and the consequence for HBV replication. The results showed that with the concentration of 6000 U/ml IFNα-2a treatment downregulated the activity of not only the Akt/mTOR signaling but also the AMPK signaling. Additionally, IFNα-2a treatment increased the formation of the autophagosomes by blocking autophagic degradation. Furthermore, IFNα-2a treatment inhibited the Akt/mTOR signaling and initiated autophagy under low and high glucose concentrations. In reverse, inhibition of autophagy using 3-methyladenine (3-MA) and glucose concentrations influenced the expression of IFNα-2a-induced ISG15 and IFITM1. Despite of ISGs induction, HBV replication and gene expression in HepG2.2.15 cells, a cell model with continuous HBV replication, were slightly increased at high doses of IFNα-2a. In conclusion, our study indicates that IFNα-2a treatment may interfere with multiple intracellular signaling pathways, facilitate autophagy initiation, and block autophagic degradation, thereby resulting in slightly enhanced HBV replication.
乙型肝炎病毒(HBV)感染可引起急性和慢性肝脏疾病,包括重型肝炎、肝硬化和肝细胞癌(HCC)。干扰素 alpha 2a(IFNα-2a)常用于治疗慢性 HBV 感染。然而,其疗效仍然相对较低。然而,成功的 IFNα-2a 治疗的免疫和分子机制仍然难以捉摸。一个问题是,增加 IFNα 剂量的应用是否会调节肝细胞中的细胞过程和 HBV 复制。在本研究中,我们专注于 IFNα 信号与其他细胞信号通路的相互作用及其对 HBV 复制的后果。结果表明,用浓度为 6000 U/ml 的 IFNα-2a 处理不仅下调了 Akt/mTOR 信号通路的活性,还下调了 AMPK 信号通路的活性。此外,IFNα-2a 处理通过阻断自噬降解增加自噬体的形成。此外,IFNα-2a 处理在低糖和高糖浓度下抑制 Akt/mTOR 信号通路并启动自噬。相反,使用 3-甲基腺嘌呤(3-MA)和葡萄糖浓度抑制自噬会影响 IFNα-2a 诱导的 ISG15 和 IFITM1 的表达。尽管诱导了 ISGs,但 HepG2.2.15 细胞(一种持续复制 HBV 的细胞模型)中的 HBV 复制和基因表达在高剂量 IFNα-2a 下略有增加。总之,我们的研究表明,IFNα-2a 处理可能会干扰多种细胞内信号通路,促进自噬的发生,并阻断自噬的降解,从而导致 HBV 复制略有增强。